Nordic Phytopharma enters lucrative agreement with US firm  

2007.02.27
Nordic Phytopharma has entered a highly lucrative agreement for its immune defence product Immolina with Jurak Corporation World Wide Inc
Nordic Phytopharma, a Danish company developing scientifically documented dietary supplements and herbal remedies, has entered a highly lucrative agreement for its immune defence product Immolina with Jurak Corporation World Wide Inc. (Jurak), a US dietary and herbal supplement network. Jurak is making an advance part-payment, and will purchase the patented substance for the next five years.
 
Carsten Wærn, managing director of Nordic Phytopharma says: "According to our information, we have received the highest advance-payment that is not tied to milestone payments, ever seen in the dietary supplement sector." The Danish company retains the rights to market Immolina in Europe and Russia, but will pay royalties on sales to Jurak.
 
"The agreement with Jurak opens channels which will enable us to introduce several new products in the years to come. Our products will now enter the US market, and a successful outcome will give us a very good reference," says Wærn.
 
Immolina is a patented dietary supplement based on bioactive microalgae complex. The technology was developed at the National Center for Natural Products Research at the University of Mississippi. The news was reported by financial daily newspaper Børsen.
 
Link > Nordic Phytopharma  

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×